Measuring inflammatory markers during routine blood tests in people with chronic obstructive pulmonary disease (COPD) could acute exacerbations at…
Articles by Patricia Inácio, PhD
AstraZeneca has acquired the exclusive rights to develop and commercialize C4X Discovery’s oral NRF2 activator for treating chronic…
Therapeutic Solutions International (TSOI) has launched a pharmaceutical spin-off — Breathe Biologics — that will take the lead in…
Depression and anxiety are highly prevalent in people with chronic obstructive pulmonary disease (COPD) a study of patients in…
People with chronic obstructive pulmonary disease (COPD) have a higher risk of developing heart disease, even if…
The digital Kaia Health mobile app helped people with chronic obstructive pulmonary disease (COPD) to better…
Among people with lung cancer who undergo tumor removal surgery, chronic obstructive pulmonary disease (COPD) is linked to a…
Older adults with chronic obstructive pulmonary disease (COPD) found the Wellinks health mobile app useful and valuable for managing the…
The U.S. Food and Drug Administration (FDA) has approved the first generic equivalent to AstraZeneca’s Symbicort (budesonide and formoterol fumarate dihydrate)…
High levels of the progenitor marker LGR6 in lung samples of chronic obstructive pulmonary disease (COPD) patients may lock…